用于原发性肝癌诊断的新型肿瘤标记物研究现状  

Current Status of Research on Novel Tumor Markers for Diagnosis of Primary Liver Cancer

作　　者：王岩[1] 吕呈 李鲁平[1] 张明香[1] 邢卓越 戴越 项丹 谷野[1] WANG Yan;LYU Cheng;LI Luping;ZHANG Mingxiang;XING Zhuoyue;DAI Yue;XIANG Dan;GU Ye(Shenyang Sixth People’s Hospital,Shenyang 110000,China)

机构地区：[1]沈阳市第六人民医院,辽宁沈阳110000

出　　处：《中国医学创新》2020年第19期169-172,共4页Medical Innovation of China

基　　金：沈阳市科技计划项目(F16-99-1-00)。

摘　　要：原发性肝癌(Primary Hepatocellular Cglcinoma,PHC)为临床中最常见的恶性肿瘤之一.PHC在我国已被列入重点筛查和预防治疗的疾病.PHC起病隐匿,临床中PHC早期多没有特征性临床表现.因此,血清学标志物的诊断价值对肝癌早期诊断尤为重要.目前,甲胎蛋白(AFP)作为诊断和监测PHC最常用的指标,具有一定的价值,但临床中小肝癌的AFP可呈阴性,同时一些慢性肝病患者的血清AFP可呈现阳性,因此,新型灵敏度及特异度高的血清肿瘤标志物,成为学者们研究的热点.现就用于原发性肝癌肿瘤标记物的研究进展做一综述.Primary Hepatocellular Cglcinoma(PHC)is a common malignant tumor in the world.In China,it has been included in one of the key malignant tumors for screening and prevention.The onset of liver cancer is insidious and has no clinical specificity in the early stage.Therefore,the diagnostic value of serological markers is particularly important for the early diagnosis of liver cancer.At present,alpha-fetoprotein is the most commonly used indicator for diagnosis and monitoring of liver cancer.However,the AFP of small liver cancer can be negative,while the serum AFP of most patients with chronic liver disease can be positive.Therefore,the new sensitivity and specificity of serum are high.Tumor markers have become a hot topic for scholars.The research progress of tumor markers for primary liver cancer is reviewed.

关 键 词：原发性肝癌 新型肿瘤标记物 研究现状 

分 类 号：R735.7[医药卫生—肿瘤]